Hip / Osteoarthritis / PRP / VAS+HOOS JR

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Hip Osteoarthritis.

The Platelet Rich Plasma “PRP” Market is valued at 828.8 Billion in 2023, and is estimated to grow to over 3 Trillion by 2032. In terms of prevalence, hip osteoarthritis is the third most common of adult men and women globally, and is commonly treated area for PRP therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Hip OA. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Hip OA cases, outcomes and other case data.